Skip to main content

Advertisement

SpringerLink
Log in

Knockdown Survivin Expression Reduces the Efficacy of Curcumin Treatment in Hepatocellular Carcinoma Cells

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Survivin is a potential therapeutic target for cancer. Increased survivin expression promotes cell survival and therapeutic resistance. However, there is little information regarding whether the expression level of survivin affects curcumin treatment in hepatocellular carcinoma (HCC).

Methods

Survivin expression was suppressed in HCC cells using a short interfering RNA (siRNA) technique. The anticancer effects of curcumin were examined using a biosensor system, MTT assay, TUNEL assay, and cell cycle analysis.

Results

Curcumin resistance developed in cells with suppressed survivin, in contrast to the parental cells, as determined by survival assays. Cell cycle analysis and TUNEL assays revealed that the apoptotic cell population was increased in the scrambled-siRNA cells treated with curcumin compared with the survivin-siRNA cells. Suppression of survivin expression resulted in curcumin resistance via the modulation of Bcl-2 and Bax expression.

Conclusions

We conclude that the expression levels of survivin may mediate the therapeutic efficacy of curcumin in HCC cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
FIG. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215–9.

    Article  PubMed  CAS  Google Scholar 

  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  PubMed  Google Scholar 

  3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.

    Article  PubMed  Google Scholar 

  4. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614–6.

    Article  PubMed  Google Scholar 

  5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.

    Article  PubMed  CAS  Google Scholar 

  6. Reed JC. The survivin saga goes in vivo. J Clin Invest. 2001;108:965–9.

    Article  PubMed  CAS  Google Scholar 

  7. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–4.

    Article  PubMed  CAS  Google Scholar 

  8. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004;6:29–40.

    PubMed  CAS  Google Scholar 

  9. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004;17:1378–85.

    Article  PubMed  CAS  Google Scholar 

  10. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125.

    Article  PubMed  Google Scholar 

  11. Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, et al. Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. Ann Surg Oncol. 2010;17:3379–85.

    Article  PubMed  Google Scholar 

  12. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs. 2010;21:326–32.

    Article  PubMed  CAS  Google Scholar 

  13. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101:1535–42.

    Article  PubMed  CAS  Google Scholar 

  14. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004;23:4921–9.

    Article  PubMed  CAS  Google Scholar 

  15. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, et al. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2007;363:738–44.

    Article  PubMed  CAS  Google Scholar 

  16. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008;267:133–64.

    Article  PubMed  CAS  Google Scholar 

  17. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol. 2007;595:127–48.

    Article  PubMed  Google Scholar 

  18. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009;11:495–510.

    Article  PubMed  CAS  Google Scholar 

  19. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. 2007;255:170–81.

    Article  PubMed  CAS  Google Scholar 

  20. Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest. 2010;28:166–71.

    Article  PubMed  CAS  Google Scholar 

  21. Chang YJ, Tai CJ, Kuo LJ, Wei PL, Liang HH, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) mediated the efficacy to curcumin treatment on hepatocellular carcinoma. Ann Surg Oncol. 2011;18:2395–403.

    Article  PubMed  Google Scholar 

  22. Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703–9.

    Article  PubMed  Google Scholar 

  23. Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–12.

    Article  PubMed  Google Scholar 

  24. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  PubMed  CAS  Google Scholar 

  25. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA. 2008;105:3690–5.

    Article  PubMed  CAS  Google Scholar 

  26. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Köhler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol. 2008;10:211–9.

    Article  PubMed  CAS  Google Scholar 

  27. Monzo M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17:2100–4.

    PubMed  CAS  Google Scholar 

  28. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas. 2001;23:251–8.

    Article  PubMed  CAS  Google Scholar 

  29. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–4.

    PubMed  CAS  Google Scholar 

  30. Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, et al. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells. Ann Surg Oncol. 2012;19:336–43.

    Article  PubMed  Google Scholar 

  31. Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, et al. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog. 2010;49:13–24.

    PubMed  CAS  Google Scholar 

  32. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091–6.

    Article  PubMed  Google Scholar 

  33. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer. 2008;44:2806–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study is supported by grant from Center of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan (DOH101-TD-C-111-008).

Author information

Authors and Affiliations

  1. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

    Chin-Sheng Hung MD, Ming-Te Huang MD, Chao-Wen Cheng PhD, Li-Jen Kuo MD, Chih-Hsiung Wu MD, PhD, Po-Li Wei MD, PhD & Yu-Jia Chang PhD

  2. Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

    Chin-Sheng Hung MD, Ming-Te Huang MD, Li-Jen Kuo MD, Chih-Hsiung Wu MD, PhD, Po-Li Wei MD, PhD & Yu-Jia Chang PhD

  3. Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan

    Chin-Sheng Hung MD, Ming-Te Huang MD, Li-Jen Kuo MD, Chih-Hsiung Wu MD, PhD, Po-Li Wei MD, PhD & Yu-Jia Chang PhD

  4. Cancer Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan

    Chin-Sheng Hung MD, Li-Jen Kuo MD, Po-Li Wei MD, PhD & Yu-Jia Chang PhD

  5. Department of Public Health, School of Public Health, Taipei Medical University, Taiwan, Taipei, Taiwan

    Hui-Hsiung Liu MD, PhD

  6. Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

    Ming-Te Huang MD & Chih-Hsiung Wu MD, PhD

  7. Center of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan

    Yuan-Soon Ho PhD & Yu-Jia Chang PhD

  8. School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

    Yuan-Soon Ho PhD & Chien-Ming Chen MS

Authors
  1. Chin-Sheng Hung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui-Hsiung Liu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming-Te Huang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao-Wen Cheng PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-Jen Kuo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuan-Soon Ho PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chih-Hsiung Wu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chien-Ming Chen MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Po-Li Wei MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yu-Jia Chang PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Po-Li Wei MD, PhD or Yu-Jia Chang PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hung, CS., Liu, HH., Huang, MT. et al. Knockdown Survivin Expression Reduces the Efficacy of Curcumin Treatment in Hepatocellular Carcinoma Cells. Ann Surg Oncol 19, 3547–3555 (2012). https://doi.org/10.1245/s10434-012-2393-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2393-4

Keywords

Search

Navigation